Akebia Therapeutics Inc.
AKBA
Market Cap$278.47M
Close$
$2.57
118% upside
Current Fair Value
118% upsideUndervalued by 118% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $278.47 Million |
|---|---|
| Enterprise Value | $279.17 Million |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $-0.28 |
| Beta | 1.18 |
| Outstanding Shares | 209,372,275 |
| Avg 30 Day Volume | 3,204,505 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -5.36 |
|---|---|
| PEG | 5.39 |
| Price to Sales | - |
| Price to Book Ratio | -1.18 |
| Enterprise Value to Revenue | 1.43 |
| Enterprise Value to EBIT | -6.06 |
| Enterprise Value to Net Income | -6 |
| Total Debt to Enterprise | 0.16 |
| Debt to Equity | -1.43 |
Revenue Sources
No data
ESG Score
No data
About Akebia Therapeutics Inc.
CEO: John Butler